A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
for Neutropenia
22 locations incl. Phoenix
Sponsor: X4 Pharmaceuticals
Sex: All·Age: 12+
Code: NCT06056297·Phase 3·Recruiting